Benitec Biopharma Inc. (NASDAQ:BNTC) to Post Q1 2025 Earnings of ($0.54) Per Share, Leerink Partnrs Forecasts

Benitec Biopharma Inc. (NASDAQ:BNTC) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Benitec Biopharma in a research note issued to investors on Monday, October 14th. Leerink Partnrs analyst M. Foroohar forecasts that the biotechnology company will earn ($0.54) per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($2.46) per share. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.50) EPS and FY2026 earnings at ($1.39) EPS.

BNTC has been the topic of a number of other reports. Leerink Partners started coverage on Benitec Biopharma in a report on Monday, July 22nd. They set an “outperform” rating and a $13.00 price target on the stock. Guggenheim started coverage on Benitec Biopharma in a report on Thursday, September 12th. They issued a “buy” rating and a $17.00 target price on the stock. Oppenheimer started coverage on Benitec Biopharma in a report on Wednesday. They issued an “outperform” rating and a $35.00 target price on the stock. Finally, JMP Securities increased their target price on Benitec Biopharma from $16.00 to $18.00 and gave the stock a “market outperform” rating in a report on Monday. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $22.60.

Benitec Biopharma Stock Performance

Benitec Biopharma stock opened at $9.81 on Thursday. The stock has a market capitalization of $91.90 million, a price-to-earnings ratio of -5.14 and a beta of 0.90. Benitec Biopharma has a 52-week low of $2.69 and a 52-week high of $12.89. The stock’s 50 day moving average price is $9.13 and its two-hundred day moving average price is $8.33.

Institutional Investors Weigh In On Benitec Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC raised its position in Benitec Biopharma by 53.0% in the 2nd quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 1,884 shares during the last quarter. Simplify Asset Management Inc. purchased a new stake in Benitec Biopharma in the 2nd quarter valued at $358,000. Janus Henderson Group PLC increased its position in shares of Benitec Biopharma by 35.5% during the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock valued at $1,266,000 after purchasing an additional 64,092 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in shares of Benitec Biopharma during the 2nd quarter valued at $5,881,000. 52.19% of the stock is owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.